Clinical Scorecard: Prognostic Factors and Treatment Outcomes for Early-Stage Hodgkin Lymphoma in Cape Town, South Africa
At a Glance
Category
Detail
Condition
Classic Hodgkin lymphoma (cHL), early-stage (modified Lugano stage I and II)
Key Mechanisms
B-cell lymphocyte neoplasm with increased risk in people living with HIV (PLWH); diagnosis complicated by tuberculosis endemicity
Target Population
Patients aged 13 years and older with early-stage cHL in a South African tertiary care setting
Care Setting
Groote Schuur Hospital, Western Cape, South Africa; state-funded tertiary academic treatment centre
Key Highlights
Early-stage cHL patients in South Africa have lower diagnosis rates (13-18%) compared to high-income countries (52-59%) due to diagnostic delays and tuberculosis overlap.
Treatment follows adapted NCCN and ESMO guidelines with two cycles of ABVD chemotherapy followed by PET/CT-guided risk-adapted therapy and involved site radiotherapy (ISRT).
Escalated BEACOPP is not used locally due to cost, complexity, and infection risk; interim PET/CT after two ABVD cycles guides further treatment.
Guideline-Based Recommendations
Diagnosis
Use modified Lugano staging (I and II) for early-stage cHL classification.
Employ PET/CT after two cycles of ABVD to assess treatment response (Deauville score ≥3 defines PET-positive).
Consider biopsy and multidisciplinary discussion for PET/CT DS 4–5 to evaluate refractory disease.
Management
Administer two cycles of ABVD chemotherapy initially.
For very good risk disease, follow with 20 Gy involved site radiation therapy (ISRT).
For intermediate/unfavourable risk, administer four cycles of ABVD plus 30 Gy ISRT.
Patients with DS 4 focal positivity receive 36 Gy ISRT after four ABVD cycles.
Offer chemotherapy-only regimens if radiotherapy is contraindicated or not feasible.
Escalated BEACOPP is not included due to resource constraints and infection risk.
Monitoring & Follow-up
Perform early interim PET/CT after two ABVD cycles to guide treatment adaptation.
Use International Working Group criteria for response assessment.
Conduct end-of-treatment PET/CT for patients with DS 4 after ISRT.
Risks
Delayed diagnosis due to tuberculosis endemicity leads to advanced disease and poorer survival.
Higher infection risk with escalated BEACOPP chemotherapy limits its use in this setting.
Patient & Prescribing Data
Early-stage cHL patients aged ≥13 years treated at a South African tertiary hospital, including PLWH.
Adapted international guidelines with ABVD chemotherapy and PET/CT-guided radiotherapy yield outcomes comparable to high-income settings despite resource constraints.
Clinical Best Practices
Prioritize early diagnosis to reduce advanced-stage presentations in tuberculosis-endemic settings.
Use interim PET/CT after two ABVD cycles for risk-adapted treatment decisions.
Apply combined modality treatment (chemotherapy plus ISRT) tailored to risk stratification.
Avoid escalated BEACOPP in resource-limited settings due to toxicity and infection risks.
Engage multidisciplinary teams for management of refractory or PET-positive disease.
